[의학신문·일간보사=정민준 기자]On the 8th, the Ministry of Food and Drug Safety (Director Kang-rip Kim) decided on the provisional manufacturing, sales suspension and collection measures for six drugs of the pharmaceutical manufacturer’Vinex’, and initiated an investigation into the relevant factory (located in Busan).
 |
This measure was determined by the Ministry of Food and Drug Safety as a precautionary measure against the submission of a recovery plan for the item manufactured by’Binex’ to the Busan Regional Food and Drug Administration. We conducted an investigation to confirm.
The six drugs that were tentatively discontinued from production and sales and recovered were amorin tablets (glimepiride), selectin capsules (fluoxetine hydrochloride), daxfen tablets (dexibuprofen), ropesin tablets 250mg (ciprofloxacin hydrochloride hydrate), and selectin capsules 10mg (fluoxetine). Hydrochloride), 1 milligram of Cadyl tablets (doxazosinmesylate).
An official from the Ministry of Food and Drug Safety said, “We plan to distribute a safety bulletin to doctors, pharmacists and consumers, etc., asking experts such as doctors and pharmacists to convert the product to other alternative medicines and cooperate so that product collection can be performed properly. And through the Health Insurance Review and Assessment Service, we requested restrictions on prescriptions for the product in hospitals and clinics.”
He said, “The Ministry of Food and Drug Safety plans to promptly carry out on-site investigations and necessary measures for’Vinex’.”
Reporter Jeong Min-joon [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>